Episode
Summit Therapeutics (SMMT): Landmark Cancer Data, a $10B Binary — We Say HOLD (~$16)
- Published
- Jul 25, 2026
- Duration seconds
- 898
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/charged-alpha-stock-encyclopedia-7819792/episodes/summit-therapeutics-smmt-landmark-cancer-data-a-10b-binary-we-say-hold-16/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/charged-alpha-stock-encyclopedia-7819792/summit-therapeutics-smmt-landmark-cancer-data-a-10b-binary-we-say-hold-16.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Summit Therapeutics Inc. (SMMT) Q2 2026 — Summit Therapeutics (SMMT) reported Q2 2026 after the close on July 23, 2026. GAAP net loss was $215.7M, or $(0.28)/share (last year's $(0.76) was inflated by a huge one-time stock-comp charge); the cleaner adjusted loss was $(0.19), a slight miss vs the ~$(0.17) estimate. Adjusted R&D jumped to $133.6M (+68% YoY) as the Phase III program scales; adjusted G&A was $18.2M. The company closed the quarter with $690.7M in cash and investments (up from $598.7M at Q1), after raising $230.8M via its ATM in Q2 plus $68.4M after quarter-end — but flagged going concern (resources insufficient for the next 12 months) and set up a new $380M ATM facility with JPMorgan. Six-month operating cash burn was $263.4M. The science broke Summit's way: the pivotal HARMONi trial's updated overall-survival analysis showed a hazard ratio of 0.76 in the full ITT population AND in both Western and Asian subgroups (Western median follow-up 23.2mo), answering the key geographic-translatability doubt; and Akeso's HARMONi-6 became the first Phase III to beat an approved PD-1 inhibitor head-to-head on OS (HR 0.66, p=0.0017) in 1L squamous NSCLC. Lead asset ivonescimab (PD-1/VEGF bispecific; Summit holds ex-China rights, Akeso licensor) has an FDA PDUFA date of November 14, 2026 in EGFR-mutated NSCLC post-TKI; HARMONi-3 (1L NSCLC) enrollment is complete with the squamous PFS readout due 2H 2026. The stock fell ~9% to ~$13.66 (near a 52-week low; 52-wk range $12.55–$30.98) on the going-concern/dilution overhang, a market cap ~$10.6B. Because SMMT is pre-revenue in its territories, we value it on a risk-adjusted sum-of-parts / reverse-DCF: net cash + probability-weighted rNPV of the ivonescimab programs lands a base fair value near $16 (~15–20% above the p…